menu
    • menu
    [{"orgOrder":0,"company":"HitGen","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Dermatology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"HitGen \/ Almirall","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ Almirall"},{"orgOrder":0,"company":"AbSci","sponsor":"Almirall","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"De novo Therapeutic Antibody","moa":"","graph1":"Dermatology","graph2":"Discovery Platform","graph3":"AbSci","amount2":0.65000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Dermatology","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"AbSci \/ Almirall","highestDevelopmentStatusID":"3","companyTruncated":"AbSci \/ Almirall"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AbSci

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            AbSci

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : De novo Therapeutic Antibody

                            Therapeutic Area : Dermatology

                            Study Phase : Discovery Platform

                            Sponsor : Almirall

                            Deal Size : $650.0 million

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Almirall and Absci Announce AI Drug Discovery Partnership to Rapidly Develop Novel Treatments for Dermatologic...

                            Details : The partnership combines Absci’s de novo AI Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            November 14, 2023

                            Lead Product(s) : De novo Therapeutic Antibody

                            Therapeutic Area : Dermatology

                            Highest Development Status : Discovery Platform

                            Sponsor : Almirall

                            Deal Size : $650.0 million

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            HitGen

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            HitGen

                            China arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Study Phase : Discovery Platform

                            Sponsor : Almirall

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            HitGen and Almirall Announce Achievement of Milestoneinn their Strategic Collaboration

                            Details : Multiple small molecule leads for an undisclosed target nominated by Almirall were the subject of this achievement. HitGen will grant exclusive rights to Almirall for further development and commercialization, and be eligible for preclinical and clinical...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 26, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Dermatology

                            Highest Development Status : Discovery Platform

                            Sponsor : Almirall

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth